ACADIA to Host Conference Call and Webcast on Wednesday, November 6,
2013, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Oct. 30, 2013—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will report its unaudited financial results for the
third quarter ended September 30, 2013 on Wednesday, November 6, 2013,
after the U.S. financial markets close. ACADIA's management will host a
conference call and webcast on Wednesday, November 6, 2013, at 5:00 p.m.
Eastern Time to discuss ACADIA’s financial results and development
programs.
The conference call may be accessed by dialing 866-953-6856 for
participants in the U.S. or Canada and 617-399-3480 for international
callers (reference passcode 85950233). A telephone replay of the
conference call may be accessed through November 20, 2013 by dialing
888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for
international callers (reference passcode 82582738). The conference call
also will be webcast live on ACADIA’s website, www.acadia-pharm.com,
under the investors section and will be archived there until November
20, 2013.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on innovative treatments
that address unmet medical needs in neurological and related central
nervous system disorders. ACADIA has a pipeline of product candidates
led by pimavanserin, which is in Phase III development as a potential
first-in-class treatment for Parkinson's disease psychosis. ACADIA also
has clinical-stage programs for chronic pain and glaucoma in
collaboration with Allergan, Inc. and two advanced preclinical programs
directed at Parkinson’s disease and other neurological disorders. All
product candidates are small molecules that emanate from discoveries
made at ACADIA. ACADIA maintains a website at www.acadia-pharm.com
to which ACADIA regularly posts copies of its press releases as well as
additional information and through which interested parties can
subscribe to receive email alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the progress and timing of ACADIA’s
drug discovery and development programs, either alone or with a partner,
including clinical trials, and the benefits to be derived from ACADIA’s
product candidates, in each case including pimavanserin. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties. Actual
events or results may differ materially from those projected in any of
such statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development and
commercialization, and collaborations with others, and the fact that
past results of clinical trials may not be indicative of future trial
results. For a discussion of these and other factors, please refer to
ACADIA’s annual report on Form 10-K for the year ended December 31, 2012
as well as ACADIA’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. This
caution is made under the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All forward-looking statements
are qualified in their entirety by this cautionary statement and ACADIA
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive
Vice President,
Chief Financial Officer and Chief Business
Officer
Lisa Barthelemy, Director of Investor Relations
(858)
558-2871